RBC Capital analyst Randall Stanicky downgraded Pfizer to Sector Perform from Outperform with a price target of $42, down from $43. The stock closed Tuesday down 50c to $38.71. Pfizer shares already reflect Covid vaccine success, making meaningful additional upside harder to justify, Stanicky tells investors in a research note. Further, competition in the Covid vaccine space “could catch up” in 2021, adds the analyst.
previous post